VYNE Therapeutics Inc.

NasdaqCM:VYNE Stock Report

Market Cap: US$27.9m

VYNE Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqCM:VYNE Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
15 Jan 25BuyUS$43,800Patrick LePoreIndividual15,000US$2.92

Insider Trading Volume

Insider Buying: VYNE insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of VYNE?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders937,7576.32%
VC/PE Firms1,116,5857.53%
Hedge Funds2,624,79317.7%
General Public5,012,19033.8%
Institutions5,138,68834.7%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 65.19% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
9.4%
Eventide Asset Management, LLC
1,394,336US$2.6m0%0.06%
9.4%
Cormorant Asset Management, LP
1,394,336US$2.6m0%0.21%
8.3%
Citadel Advisors LLC
1,230,457US$2.3m3.63%no data
7.53%
Access Industries, Inc.
1,116,585US$2.1m0%0.04%
4.7%
Delaware Street Capital, L.L.C.
696,465US$1.3m0%11.21%
3.21%
David Domzalski
476,061US$895.0k-4.15%no data
3.2%
The Vanguard Group, Inc.
475,129US$893.2k7.13%no data
3.08%
Acorn Bioventures
456,970US$859.1k0%0.66%
3%
Palo Alto Investors LP
445,434US$837.4k0%0.16%
2.38%
Exome Asset Management LLC
353,434US$664.5k0%0.63%
1.66%
UBS O'Connor LLC
245,800US$462.1k0%0.05%
1.19%
Schonfeld Strategic Advisors LLC
176,658US$332.1k4.78%no data
1.04%
Adage Capital Management, L.P.
154,134US$289.8k0%no data
1.03%
Parkman Healthcare Partners LLC
152,973US$287.6k-24.6%0.04%
0.97%
Mutya Harsch
144,329US$271.3k-3.15%no data
0.91%
Geode Capital Management, LLC
135,017US$253.8k0.32%no data
0.87%
Iain Stuart
128,637US$241.8k-3.64%no data
0.86%
Tyler Zeronda
126,892US$238.6k-3.55%no data
0.56%
BlackRock, Inc.
83,314US$156.6k0.29%no data
0.48%
Susquehanna International Group, LLP, Asset Management Arm
70,832US$133.2k17.4%no data
0.4%
Prelude Capital Management, LLC
59,400US$111.7k-8.82%0.01%
0.35%
Patrick LePore
51,472US$96.8k41.1%no data
0.25%
Bridgeway Capital Management, LLC
36,958US$69.5k0%no data
0.25%
Staley Capital Advisers, Inc.
36,472US$68.6k0%no data
0.17%
Renaissance Technologies LLC
24,943US$46.9k-71.2%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/03/12 12:40
End of Day Share Price 2025/03/12 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

VYNE Therapeutics Inc. is covered by 12 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Douglas TsaoBarclays
Jason Matthew GerberryBofA Global Research
Julian HarrisonBTIG